The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade II Cerebral Gliomas in Adults: Version 2019.01The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade II Cerebral Gliomas in Adults: Version 2019.01
- Other Titles
- The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade II Cerebral Gliomas in Adults: Version 2019.01
- Authors
- 김영준; 김재용; 위찬우; Tae Hoon Roh; 홍제범; Hyuk-Jin Oh; 강석구; Shin Hyuk Kang; Doo-Sik Kong; 김성환; Se-Hyuk Kim; 김세훈; 김유정; 김의현; 김인아; Ho Sung Kim; Jae-Sung Park; Hyun Jin Park; Sang Woo Song; Kyoung-Su Sung; 양승호; Wan-Soo Yoon; 윤홍인; 이지혜; 이순태; Sea-Won Lee; 이연수; 임재준; 장종희; Tae-Young Jung; 정혜림; 조재호; 최승홍; Hyoung Soo Choi; 임도훈; 정동섭
- Issue Date
- 2019
- Publisher
- 대한뇌종양학회
- Keywords
- Korean Society for Neuro-Oncology; Guideline; Grade II Gliomas; Practice
- Citation
- Brain Tumor Research and Treatment, v.7, no.2, pp.74 - 84
- Journal Title
- Brain Tumor Research and Treatment
- Volume
- 7
- Number
- 2
- Start Page
- 74
- End Page
- 84
- URI
- https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/4044
- DOI
- 10.14791/btrt.2019.7.e43
- ISSN
- 2288-2405
- Abstract
- Background: There was no practical guideline for the management of patients with central nervous system tumor in Korea for many years. Thus, the Korean Society for Neuro-Oncology (KSNO), a multidisciplinary academic society, has developed the guideline for glioblastoma. Subsequently, the KSNO guideline for World Health Organization (WHO) grade II cerebral glioma in adults is established.
Methods: The Working Group was composed of 35 multidisciplinary medical experts in Korea. References were identified by searching PubMed, MEDLINE, EMBASE, and Cochrane CENTRAL databases using specific and sensitive keywords as well as combinations of keywords regarding diffuse astrocytoma and oligodendroglioma of brain in adults.
Results: Whenever radiological feature suggests lower grade glioma, the maximal safe resection if feasible is recommended globally. After molecular and histological examinations, patients with diffuse astrocytoma, isocitrate dehydrogenase (IDH)-wildtype without molecular feature of glioblastoma should be primarily treated by standard brain radiotherapy and adjuvant temozolomide chemotherapy (Level III) while those with molecular feature of glioblastoma should be treated following the protocol for glioblastomas. In terms of patients with diffuse astrocytoma, IDH-mutant and oligodendroglioma (IDH-mutant and 1p19q codeletion), standard brain radiotherapy and adjuvant PCV (procarbazine+lomustine+vincristine) combination chemotherapy should be considered primarily for the high-risk group while observation with regular follow up should be considered for the low-risk group.
Conclusion: The KSNO's guideline recommends that WHO grade II gliomas should be treated by maximal safe resection, if feasible, followed by radiotherapy and/or chemotherapy according to molecular and histological features of tumors and clinical characteristics of patients.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Neurosurgery > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/4044)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.